CAMBRIDGE, MA, eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the close of a $191 million Series D financing.
eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the close of a $191 million Series D financing. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance pipeline programs as well as scale production.
The financing was led by Lux Capital, with participation from existing investors ARCH Ventures, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, and Leaps by Bayer as well as new investors DaVita, Eisai Innovation, NATCO Pharmaceuticals, and Parkwood Corporation.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
By VC News Daily
Source: VC News Daily